Manufacturers Provide SEC GMP Enforcement Updates
This article was originally published in The Gold Sheet
Executive Summary
Recent portrayals of drug GMP enforcement activity in reports to stockholders ran the gamut from acknowledging the likelihood of adverse financial impacts to suggesting that remediation in response to 483s must be going well because there hasn’t been a warning letter.